Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis Study of evaluating SPARC expression

Phase II Study of Carboplatin+nab-Paclitaxel for Non-small Cell Lung Cancer with Interstitial Pneumonitis Study of evaluating SPARC expression - Study of evaluating SPARC expression in Lung Cancer with Interstitial Pneumonitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016071

Enrollment

Registered

2014-12-28

Start date

2014-12-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell carcinoma with interstitial pneumoniae

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The cases enrolled onto the YLOG0114 study whose pathological speciemens obtained at diagnosis can be suitable for immunohistchemistory evaluation.

Exclusion criteria

Exclusion criteria: The cases excepting the above.

Design outcomes

Primary

Measure	Time frame
To evaluate the SPARC expression level of the tumor cells and interstitial cells utlizing the pathological specimens obtained from patients enrolled to the YLOG0114 study.	—

Secondary

Measure	Time frame
To evaluate the relationship between SPARC expression leve, other factores and treatment effectiveness.	—

Countries

Japan

Contacts

Public ContactHiroyuki Sakashita

Postgraduate School of Tokyo Medical and Dental University Division of Clinical Oncology

hsakpulm@tmd.ac.jp03-5803-5954

Outcome results